Tenax Therapeutics shares are trading higher after the company received new US patent covering oral levosimendan (TNX-103) for pulmonary hypertension with heart failure with preserved ejection fraction, expiring in 2040.
Portfolio Pulse from Benzinga Newsdesk
Tenax Therapeutics has received a new US patent for oral levosimendan (TNX-103) for pulmonary hypertension with heart failure with preserved ejection fraction, which will expire in 2040. This has led to a rise in the company's share prices.
July 19, 2023 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The new patent for Tenax Therapeutics' oral levosimendan (TNX-103) has led to a rise in the company's share prices.
The new patent for oral levosimendan (TNX-103) provides Tenax Therapeutics with exclusive rights to the drug until 2040. This is a significant development for the company, which has led to an increase in its share prices. The patent is directly related to the company's core business, making it highly relevant. The importance is high as it impacts the company's competitive position and future revenue streams. The confidence in the analysis is high based on the direct correlation between patent approval and stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100